Rationally improving T cell-mediated immunotherapy using Sleeping Beauty mutagenesis

利用睡美人诱变合理改进 T 细胞介导的免疫治疗

• 批准号: 10238780
• 负责人: Laura Marie Rogers
• 金额: $ 18.58万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10238780
• 关键词: Address; Adoptive Transfer; Applications Grants; Bioinformatics; Cancer Model; Cancer Patient; Candidate Disease Gene; Doctor of Philosophy; Environment; Faculty; Foundations; Funding; Genes; Genetic Screening; Goals; Holden Comprehensive Cancer Center at the University of Iowa; Immune; Immunocompetent; Immunotherapeutic agent; Immunotherapy; Institution; Interdisciplinary Study; Iowa; K22 Award; Knock-out; Lead; Lymphoma; Mediating; Mentors; Modeling; Mus; Mutagenesis; Mutate; Mutation; Patients; Positioning Attribute; Pre-Clinical Model; Prevalence; Process; Research; Research Personnel; Series; Sleeping Beauty; System; Systems Biology; T cell therapy; T-Lymphocyte; Technical Expertise; Testing; Therapeutic; Training; Tumor-infiltrating immune cells; Universities; Work; anti-PD-1; anti-PD1 therapy; antitumor effect; base; cancer immunotherapy; cancer therapy; cancer type; career; chimeric antigen receptor T cells; cohort; design; experience; experimental study; gene discovery; immune checkpoint blockade; improved; innovation; interest; loss of function mutation; melanoma; mouse model; novel; novel strategies; novel therapeutics; overexpression; patient population; programs; public health relevance; screening; skills; small hairpin RNA; success; tenure track; therapeutic gene; therapeutic target; treatment strategy; tumor; tumor immunology; tumor microenvironment; whole genome

Project Summary/Abstract I, Dr. Laura Rogers, PhD, am currently a mentored postdoctoral researcher at the University of Iowa Holden Comprehensive Cancer Center. I intend to pursue an independent tenure-track faculty position at a competitive research institution, so that I may continue to expand the exciting translational cancer immunotherapy project I have developed during my postdoctoral research career. This project aims to address a major problem in the dynamic field of cancer immunotherapy, namely, how to help cancer patients who lack intratumoral T cells respond more robustly to immunotherapy. I have devised a genetic screen approach to identify T cell genes that impact intratumoral T cell accumulation using Sleeping Beauty (SB) mutagenesis in two immunocompetent murine models of cancer (melanoma and lymphoma). We have identified a number of novel candidate immunotherapy targets that may enhance T cell mediated immunotherapies, including CAR-T cell adoptive transfer and immune checkpoint blockade (anti-PD-1). Aim 1 of this proposal directly tests the impact of promising candidate, Aak1, on T cell infiltration into tumors and its effect on anti-PD-1 efficacy, and Aim 2 expands on a successful pilot screen in order to identify additional candidates targets that are likely to synergize with anti-PD-1 therapy. Together these studies will promote the rational design of novel immunotherapeutic agents to enhance existing cancer therapy. I have extensive experience using SB mutagenesis, and my current training environment has allowed me to expand my research interests into the cancer immunotherapy field. The K22 award will be highly beneficial to my transition into an independent investigator, in part by allowing me to gain technical expertise in bioinformatics analysis as I seek formal training through the Masters in Bioinformatics program at the University of Iowa. These critical skills will allow me to fluently address pressing questions within the cancer immunology field, where the complexity of the tumor microenvironment necessitates a systems biology approach. Finally, my plan to advance to an independent investigator and establish a competitive independent research program includes applying for R01 level funding for this project in 2018. The K22 award will facilitate this process greatly, as the proposed work would lay the scientific foundation for a mechanistic grant proposal. Combined with my unique background and novel approach, NCI's K22 will help me launch a highly impactful, interdisciplinary research career in translational cancer immunology.

项目概要/摘要 我，劳拉·罗杰斯博士，博士，目前是爱荷华大学霍尔顿分校的指导博士后研究员 综合癌症中心。我打算在竞争激烈的大学中寻求独立的终身教授职位 研究机构，以便我可以继续扩展令人兴奋的转化癌症免疫治疗项目 在我的博士后研究生涯中得到了发展。该项目旨在解决一个主要问题 癌症免疫治疗的动态领域，即如何帮助缺乏瘤内T细胞的癌症患者 对免疫疗法的反应更加强烈。我设计了一种基因筛选方法来识别 T 细胞基因 使用睡美人 (SB) 诱变影响两个肿瘤内 T 细胞的积累 免疫活性小鼠癌症模型（黑色素瘤和淋巴瘤）。我们已经确定了一些新颖的 可能增强 T 细胞介导的免疫治疗的候选免疫治疗靶点，包括 CAR-T 细胞 过继转移和免疫检查点阻断（抗 PD-1）。该提案的目标1直接测试影响 有前途的候选药物 Aak1 对 T 细胞浸润肿瘤及其对抗 PD-1 功效的影响以及目标 2 扩展成功的试点屏幕，以确定可能的其他候选人目标 与抗PD-1治疗有协同作用。这些研究将共同​​促进小说的合理设计 免疫治疗剂可增强现有的癌症治疗。我有丰富的使用 SB 的经验 诱变，我目前的培训环境使我能够将我的研究兴趣扩展到 癌症免疫治疗领域。 K22 奖项对于我转型为独立人士非常有帮助 研究员，部分是通过让我在寻求正式的生物信息学分析方面获得技术专业知识 通过爱荷华大学生物信息学硕士课程进行培训。这些关键技能将使 我能够流利地解决癌症免疫学领域内的紧迫问题，其中癌症免疫学的复杂性 肿瘤微环境需要系统生物学方法。最后，我的升职计划是 独立研究者并建立有竞争力的独立研究计划，包括申请 R01 2018 年该项目的资金水平。K22 奖将​​极大地促进这一进程，因为拟议的工作 将为机械拨款提案奠定科学基础。结合我独特的背景和 NCI 的 K22 是一种新颖的方法，将帮助我在以下领域开展极具影响力的跨学科研究生涯 转化癌症免疫学。